<DOC>
	<DOCNO>NCT00706654</DOCNO>
	<brief_summary>The purpose trial evaluate efficacy , safety , tolerability intramuscular ( IM ) depot formulation aripiprazole maintenance treatment patient schizophrenia The trial design three treatment phase . Phase 1 design allow subject convert current anti-psychotic treatment oral non-generic aripiprazole monotherapy ( oral conversion phase 4 6 week ) . During Phase 2 subject stabilize oral non-generic aripiprazole monotherapy . Once subject stabilize Phase 2 ( oral stabilization phase minimum 8 week maximum 28 week ) , eligible randomize double-blind IM depot maintenance phase , Phase 3 . During Phase 3 , subject assess exacerbation psychotic symptom impend relapse 38 week .</brief_summary>
	<brief_title>Intramuscular Depot Formulation Aripiprazole Maintenance Treatment Patients With Schizophrenia</brief_title>
	<detailed_description>This randomize , double-blind , active-controlled study consist screen phase 3 treatment phase . Eligibility determine screen phase 2 42 day . Subjects currently receive oral treatment anti-psychotic non-generic aripiprazole enter Phase 1 , subject lapse aripiprazole anti-psychotic treatment time study entry ( `` lapse '' define &gt; 3 consecutive day without medication ) enter directly Phase 2 . During Phase 1 ( oral conversion ) , subject cross-titrated weekly visit anti-psychotics oral non-generic aripiprazole monotherapy minimum 4 week maximum 6 week . During Phase 2 ( minimum 8 week maximum 28 week duration ) , subject assess bi-weekly stabilized oral dose aripiprazole range 10 mg 30 mg daily . After stability criterion meet Phase 2 , subject eligible randomized double-blind IM depot maintenance phase , Phase 3 . Subjects randomize 2:2:1 ( aripiprazole IM depot 300-400 mg monthly , oral aripiprazole 10-30 mg daily , aripiprazole IM depot 25-50 mg monthly ) . During Phase 3 subject assess impend relapse/exacerbation psychotic symptom . If subject identify impend relapse/exacerbation psychotic symptom , withdraw trial give opportunity enroll open-label aripiprazole IM depot trial , 31-08-248 ( NCT00731549 ) . Alternatively , subject discontinues Phase 3 ( include Week 38 ) option enroll open-label aripiprazole IM depot trial , 31-08-248 ( NCT00731549 ) . The enrollment figure include re-screened patient .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Subjects able provide write informed consent and/or consent obtain legally acceptable representative ( require Institutional Review Board/Independent Ethics Committee [ IRB/IEC ] ) , prior initiation protocolrequired procedure . Male female subject 18 60 year age , inclusive , time informed consent . Subjects current diagnosis schizophrenia define Diagnostic Statistical Manual Mental Disorders , version 4 , Text Revision ( DSMIVTR ) criteria history illness least 3 year prior screen . Subjects , investigator 's judgment , require chronic treatment antipsychotic medication . Subjects able understand nature study follow protocol requirement , include prescribed dosage regimen , tablet ingestion , IM depot injection , discontinuation prohibit concomitant medication , read understand write word order complete patientreported outcome measure , reliably rat assessment scale . Subjects current DSMIVTR diagnosis schizophrenia , include schizoaffective disorder , major depressive disorder , bipolar disorder , delirium , dementia , amnestic , cognitive disorder . Also , subject borderline , paranoid , histrionic , schizotypal , schizoid , antisocial personality disorder . Subjects schizophrenia consider resistant/refractory antipsychotic treatment history response clozapine . Subjects significant risk violent behavior significant risk commit suicide base history investigator 's judgment . Subjects currently meet DSMIVTR criterion substance dependence ; include alcohol benzodiazepine , exclude caffeine nicotine , 2 positive drug screen cocaine . Subjects know allergic , intolerant , unresponsive prior treatment aripiprazole quinolinones , hypersensitivity antipsychotic agent , include aripiprazole . Subjects history neuroleptic malignant syndrome clinically significant tardive dyskinesia screening . Subjects uncontrolled thyroid function abnormality . Subjects history seizure , neuroleptic malignant syndrome , clinically significant tardive dyskinesia , medical condition would expose subject undue risk interfere study assessment . Subjects involuntarily incarcerate . Subjects undergone electroconvulsive therapy within 180 day entry Phase 2 . Subjects use investigational agent within 30 day screen ; prior participation clinical study aripiprazole IM depot . Subjects clinically significant abnormality laboratory test result , vital sign , ECG result . Subjects hospitalize 30 day 90 day prior Phase 1 ( Phase 2 subject bypass Phase 1 ) . Subjects require 1 benzodiazepine beyond screen ( eg , lorazepam oxazepam ) . Subjects fail washout prohibit concomitant medication , include use CYP2D6 CYP3A4 inhibitor CYP3A4 inducer , antipsychotic , antidepressant ( include monoamine oxidase inhibitor [ MAOI ] ) , mood stabilizer , screen Phase 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Aripiprazole</keyword>
	<keyword>Intramuscular ( IM ) depot</keyword>
	<keyword>Schizophrenia</keyword>
</DOC>